FULL HEALTH ACETYL L CARNITINE 500MG 60 VCAPS

Μορφή – Συσκευασία: 60 φυτοκάψουλες ανά συσκευασία

Barcode: 5200421900223

ΧΩΡΙΣ στεατικό μαγνήσιο και αμφισβητούμενα έκδοχα 

ΧΩΡΙΣ: τεχνητά χρώματα, αρώματα, συντηρητικά, μαγιά και γενετικά τροποποιημένα συστατικά. 

ΔΡΑΣΤΙΚΑ ΣΥΣΤΑΤΙΚΑ: Ακετυλο-καρνιτίνη (acetyl-l-carnitine).

ΑΛΛΑ ΣΥΣΤΑΤΙΚΑ: Υλικό κάψουλας (φυτική κυτταρίνη).

ΧΩΡΙΣ: τεχνητά χρώματα, αρώματα, συντηρητικά, μαγιά και γενετικά τροποποιημένα συστατικά.

1. Rebouche CJ. Carnitine. In: Modern Nutrition in Health and Disease, 9th Edition (edited by Shils ME, Olson JA, Shike M, Ross, AC). Lippincott Williams and Wilkins, New York, 1999, pp. 505-12.

2. The editors. Carnitine: lessons from one hundred years of research. Ann NY Acad Sci 2004;1033:ix-xi. 3. National Research Council. Food and Nutrition Board. Recommended Dietary Allowances, 10th Edition. (https://www.nap.edu/catalog/1349/recommended-dietary-allowances-10th-edition) National Academy Press, Washington, DC, 1989.

4. Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes. (https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-carbohydrate-¦ber-fat-fattyacids-cholesterol-protein-and-amino-acids) 2005. http://www.iom.edu/project.asp?id=4574.

5. Stanley CA. Carnitine de¦ciency disorders in children. Ann NY Acad Sci 2004;1033:42-51. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591002?dopt=Abstract)] ½.

6.Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 2004;1033:30-41. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591001?dopt=Abstract)]

7. Foster DW. The role of the carnitine system in human metabolism. Ann NY Acad Sci 2004;1033:1-16. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15590999? dopt=Abstract)] ¾.

8.Liu J, Head E, Kuratsune H, Cotman CW, Ames BN. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY Acad Sci 2004;1033:117-31. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591009?dopt=Abstract)]

9. Brass EP, Hiatt WR. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J Am Coll Nutr 1998;17:207-15. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/9627906?dopt=Abstract)]

10. Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr 2000;72:618S-23S. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10919968?dopt=Abstract)]

11. Brass EP. Carnitine and sports medicine: use or abuse? Ann NY Acad Sci 2004;1033:67-78. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591004?dopt=Abstract)]

12. Ames BN, Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann NY Acad Sci 2004;1033:108-16. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591008? dopt=Abstract)] 13. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN. Feeding acetyl-L-carnitine and lipoic acid to old rats signi¦cantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA 2002;99:1870-5. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11854487?dopt=Abstract)]

14. Liu J, Killilea D, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding a¨nity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-a-lipoic acid. Proc Natl Acad Sci USA 2002;99:1876-81. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11854488?dopt=Abstract)]

15. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-a-lipoic acid. Proc Natl Acad Sci USA 2002;99:2356-61. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11854529? dopt=Abstract)]

16. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 2003;18:61-71. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/12598816?dopt=Abstract)]

17. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004;1033:79-91. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591005?dopt=Abstract)]

18. Hiatt WR. Carnitine and peripheral arterial disease. Ann NY Acad Sci 2004;1033:92-8. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591006?dopt=Abstract)]

19. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with Lcarnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006;106:215-23. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/16685128?dopt=Abstract)] 20. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc 2013;88:544-51. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/23597877? dopt=Abstract)] 21. Brevetti G, Diehm C, Lambert D. European multicenter study on priopionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10551714?dopt=Abstract)]

22. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11382369?dopt=Abstract)]

23. Brass EP, Koster D, Hiatt WR, Amato A. A systematic review and meta-analysis of propionyl-Lcarnitine effects on exercise performance in patients with claudication. Vasc Med 2013;18:3- 12. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/23321261?dopt=Abstract)]

24. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, Didonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576-85. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/23563705?dopt=Abstract)]

25. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P, Portenoy R, Esteban-Cruciani N. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine de¦ciency: a preliminaryanalysis. Ann NY Acad Sci 2004;1033:168-76. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591014?dopt=Abstract)]

26. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, De Caetano A, Giordani P, Testa E, Lai V. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 2002;86:1854-7. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/12085175?dopt=Abstract)]

27. Mingrone G. Carnitine in type 2 diabetes. Ann NY Acad Sci 2004;1033:99-107. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591007?dopt=Abstract)]

28. De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999;18:289-95. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/12038470?dopt=Abstract)]

29. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G. Lcarnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999;77-82. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10067662?dopt=Abstract)]

30. Sima AAF, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005;28:89-94. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15616239?dopt=Abstract)]

31. Day L, Shikuma C, Gerschenson M. Acetyl-L-carnitine for the treatment of HIV lipoatrophy. Ann NY Acad Sci 2004;1033:139-46. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591011?dopt=Abstract)]

32. Ilias I, Manoli I, Blackman MR, Gold PW, Slesci S. L-carnitine and acetyl-L-carnitine in the treatment of complications associated with HIV infection and antiretroviral therapy. Mitochondrion 2004;4:163-8. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/16120381? dopt=Abstract)]

33. Moretti S, Alesse E, Di Marzio L, Zazzeroni F, Ruggeri B, Marcellini S, Famularo G, Steinberg SM, Boschini A, Cifone MG, De Simone C. Effect of L-carnitine on human immunode¦ciency virus-1 infection-associated apoptosis: a pilot study. Blood 1998;91:3817-24. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/9573019?dopt=Abstract)]

34. Di Marzio L, Moretti S, D’Alò S, Zazzeroni F, Marcellini S, Smacchia C, Alesse E, Cifone MG, De Simone C. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol 1999;92:103-10. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10413658?dopt=Abstract)]

35. Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997;2:250-2. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10975731?dopt=Abstract)]

36. Simpson DM, Katzenstein D, Haidich B, Millington D, Yiannoutsos C, Schi¦tto G, McArthur J. Plasma carnitine in HIV-associated neuropathy. AIDS 2001;15:2207-8. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11684949?dopt=Abstract)]

37. Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, Cargnel A, Mariani C. Acetyl-l-carnitine in the treatment of painful antiretroviral neuropathy in human immunode¦ciency virus patients: an open label study. J Peripher Nerv Syst 2006;11:72-6. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/16519785?dopt=Abstract)]

38. De Simone C, Famularo G, Tzantzoglou S, Trinchieri V, Moretti S, Sorice F. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS 1994;8:655-60. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/7914733?dopt=Abstract)]

39. Loignon M, Toma E. L-carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 2001;15:1194-5. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11416731?dopt=Abstract)]

40. Mauss S, Schmutz G. L-carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Med 2001:2:59-60. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11737377? dopt=Abstract)]

41. Calvani M, Benatti P, Mancinelli A, D’Iddio S, Giordano V, Koverech A, Amato A, Brass EP. Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004;1033:52-66. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591003? dopt=Abstract)]

42. Hurot J-M, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002;13:708-14. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11856775?dopt=Abstract)]

43. Menchini-Fabris GF, Canale D, Izzo PL, Olivieri L, Bartelloni M. Free L-carnitine in human semen: its variability in different andrologic pathologies. Fertil Steril 1984;42:263-7. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/6430725?dopt=Abstract)]

44. Matalliotakis I, Koumantaki Y, Evageliou A, Matalliotakis G, Goumenou A, Koumantakis E. Lcarnitine levels in the seminal plasma of fertile and infertile men: correlation with sperm quality. Int J Fertil Womens Med 2000;45:236-40. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10929687?dopt=Abstract)]

45. Costa M, Canale D, Filicori M, D’Iddio S, Lenzi A. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Italian study group on carnitine and male infertility. Andrologia 1994;3:155- 9. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/8085668?dopt=Abstract)]

46. Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res 1995;21:157-9. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/8529529?dopt=Abstract)]

47. Vicari E, Calogero AE. Effects of treatment with carnitines in infertile patients with prostatovesiculo-epididymitis. Hum Reprod 2001;16:2338-42. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/11679516?dopt=Abstract)]

48. Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L, Dondero F, Gandini L. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril 2003;79:292-300. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/12568837? dopt=Abstract)]

49. Ng CM, Blackman MR, Wang C, Swerdloff RS. The role of carnitine in the male reproductive system. Ann NY Acad Sci 2004;1033:177-88. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/15591015?dopt=Abstract)]

50. Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2006;85(5):1409-14. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/16600222? dopt=Abstract)]

51. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002;54:589-98. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/12429869? dopt=Abstract)]

52. Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991;119:799-802. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/1941389?dopt=Abstract)]

53. Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, Couceiro J, Camina F, Rodriguez-Segade S. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998;13:546-9. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/9853647?dopt=Abstract)]

54. Verrotti A, Greco R, Morgese G, Chiarelli F. Carnitine de¦ciency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999;29:36-40. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/10356662?dopt=Abstract)]

55. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009;47:101-11. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/19280426?dopt=Abstract)]

56. U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=32488). November 1989.

57. Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010;44:1287-93. [PubMed abstract (https://www.ncbi.nlm.nih.gov/pubmed/20587742?dopt=Abstract)]

Προειδοποιήσεις: Να μη γίνεται υπέρβαση της συνιστώμενης ημερήσιας δόσης, τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μιας ισορροπημένης δίαιτας, το προϊόν αυτό δεν προορίζεται για την πρόληψη, αγωγή ή θεραπεία ανθρώπινης νόσου, συμβουλευτείτε τον γιατρό σας αν είστε έγκυος, θηλάζετε, βρίσκεστε υπό φαρμακευτική αγωγή ή αντιμετωπίζεται προβλήματα υγείας, να φυλάσσεται μακριά απο τα μικρά παιδιά.

Επισήμανση: Οι θέσεις, οι απόψεις και τα συμπεράσματα είναι προϊόν εκτεταμένης βιβλιογραφικής έρευνας, στηρίζονται σε δημοσιευμένες μελέτες και άρθρα που έχουν δημοσιευτεί σε έγκριτα επιστημονικά περιοδικά και σε καμία περίπτωση δεν μπορούν να αντικαταστήσουν, υποκαταστήσουν ή να αλλοιώσουν ιατρικές γνωματεύσεις, αγωγές ή ένα ισορροπημένο διαιτολόγιο. Σας παροτρύνουμε να συμβουλεύεστε τους επαγγελματίες υγείας (γιατρό, φαρμακοποιό και διαιτολόγο-διατροφολόγο με άδεια άσκησης επαγγέλματος) για τη χρήση των συμπληρωμάτων διατροφής, καθώς είναι οι αρμόδιοι για να κρίνουν και να αξιολογήσουν συνολικά την κατάσταση της υγείας σας. Τέλος, γίνεται αναφορά και λαμβάνονται υπόψιν οι Ευρωπαϊκοί ισχυρισμοί υγείας, όπως ορίζονται από την Ευρωπαϊκή Αρχή για την Ασφάλεια των Τροφίμων και οι σχετικές μονογραφίες από τον ΕΜΑ (European Medicines Agency) για τα φαρμακευτικά προϊόντα φυτικής προέλευσης – Herbal Medicinal Products (HMPC).